{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-136785","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.365824+00:00","generated_at":"2026-06-02T02:22:35.073849+00:00","sec_items":["1.01","3.02","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company","bullets":["OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.","Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.","OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).","Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.","Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-136785","json":"https://secwatch.observer/filing/0001193125-24-136785.json","markdown":"https://secwatch.observer/filing/0001193125-24-136785.md","text":"https://secwatch.observer/filing/0001193125-24-136785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:22:35.073849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c41110b87","claim":"Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"}]},{"claim_id":"7478c412a4","claim":"Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"}]},{"claim_id":"c558459de6","claim":"Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..","evidence_excerpt":"each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"}]},{"claim_id":"1746ee1b50689d1d968bbff32e986f17c69ed14a","claim":"OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Reneo Pharmaceuticals, Inc."},{"label":"Effective","value":"2024-05-10"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}